ASH 2024

RRMM - a lot of options to choose from

NDMM - upfront bispecifics and CAR-T cells!?

High-risk smoldering myeloma: should we treat it and how?

Belantamab mafodotin in 1st line of transplant-ineligible patients

The holy grail of MRD-negativity

Great new developments in first-line therapy!

NDMM: Strong performance by GMMG!

Maintenance to end all maintenance

Reshaping treatment decision-making in Newly Diagnosed Multiple Myeloma

Reducing waste in Myeloma

Treatment of smoldering myeloma

24hrs urine collection no longer necessary for follow-up!

NDMM: Starker Auftritt der GMMG!

Tolle neue Entwicklungen in der Erstlinientherapie!

24-Stunden-Urinsammlung im Follow-Up nicht mehr erforderlich!

Belantamab Mafodotin in der Erstbehandlung der nicht transplantierten Patienten

Therapie des Smoldering Myeloms

Belantamab-Vd is the SOC in 2nd line – if cilta-cel is not accessable ...

Exciting development in CAR-T cell therapy for multiple myeloma

Precision medicine dissects mechanisms of resistance/response to BCL2 inhibitors in t(11;14) MM - the critical role of comprehensive genomic profiling through WGS

Tocilizumab prophylaxis for RRMM patients treated with teclistamab, elranatamab or talquetama

Combination of elranatamab + carfilzomib + dexamethasone in the phase 1b MagnetisMM-20 study

A new trispecific to beat them all?

Belantamab-Vd er beste standard, hvis cilta-cel ikke er tilgjengelig ...

Spannende Entwicklung in der CAR-T-Zelltherapie beim Multiplen Myelom

Et nytt trispesifikt antistoff, best av dem alle?

It's time to treat smoldering myeloma!

Daratumumab in smoldering myeloma

Det er på tide å behandle ulmende myelomatose

Daratumumab beim Smoldering Myelom

Different strategies for the treatment of R/R Follicular Lymphoma: CAR-T, T-Cell Engagers, and Novel Combinations

1st results of the phase III study inMIND

A new anti-CD19 / anti-CD3 monoclonal bispecific antibody

Bispecific antibodies: A new option in the 1st line of follicular lymphoma?

Primi risultati dello studio di fase III inMIND

Un nuovo anticorpo bispecifico anti-CD19/anti-CD3 per il linfoma follicolare recidivato/refrattario

Bispezifische Antikörper: Eine neue Option in der 1st line des Follikulären Lymphoms?

5-year follow-up of ZUMA-5

Aggiornamento a 5 anni dello studio di fase II ZUMA-5

Progress in MCL: Treatment Patterns, Post-CAR-T Outcomes, and Emerging Combination Strategies

Practice Changing Data at ASH in MCL

The era of ASCT Consolidation in first line might have ended for many younger patients with MCL

Rituximab maintenance necessary after TRIANGLE?

ASH Highlight: Is chemotherapy still necessary for mantle cell lymphoma?

Primary results of the ENRICH trial

ALTAMIRA - a nordic trial for elderly patients with MCL

Synergistic chemo-free triplets ALR y ALO in first line for patients with MCL of all ages

TRIANGLE: New standard in first-line therapy

Could older patients with MCL be treated without chemotherapy in first line?

Sometimes, more is better: the VIPOR regimen for untreated MCL

Interim results of the OASIS II trial

European TRIANGLE study for younger patients with MCL

ENRICH for elderly patients with MCL

¿Podríamos tratar sin quimioterapia a los pacientes mayores con LCM en 1 línea?

ASH Highlight: Ist die Chemotherapie beim Mantelzell-Lymphom noch notwendig?

TRIANGLE: Der neue Standard in der Erstlinientherapie

Sinergia con los tripletes sin quimio ALR y ALO en primera línea para pacientes con LCM de todas las edades

A veces, más sí es mejor: esquema VIPOR para LCM en primera línea

El TAPH de consolidación en primera línea será historia por fin para muchos pacientes jóvenes con LCM

Rituximab-Erhaltung nach TRIANGLE notwendig?

ENRICH - vad blir standardbehandling för äldre patienter med mantelcellslymfom?

TRIANGLE - en studie från det Europeiska nätverket för mantelcellslymfom, för patienter <65 år

ALTAMIRA- en nordisk studie för äldre patienter med mantelcellslymfom. Risk- och responsstyrd behandling

Advances in CLL Treatment: Novel Therapies and Comparative Trials in BTK Inhibitor-Experienced and First-Line Settings

Pirtobrutinib is superior to investigator's choice in BRUIN CLL-321

Sonrotoclax + Zanubrutinib in treatment naive CLL

5-year update from Polarix trial

Initial efficacy and safety data for combination of Golcadomide + R-CHOP

Impressive results for fixed-duration Epcoritamab + R-CHOP